# Associations of Healthcare Costs and Early Detection with Colorectal Cancer Mortality in Canada

Yulin Yuan, Ruohan Sun, Tony Lee

April 9, 2025

#### Introduction

## Study Objective

The objective of this study is to evaluate how healthcare expenditures and early detection of colorectal cancer are associated with patient mortality outcomes in Canada. Our goal is to explore whether patients whose cancer is detected at an early stage, and those who bear different levels of healthcare costs, exhibit significantly different mortality rates. Through statistical analysis of available data, we will quantify the strength of these associations and assess their significance. We can build on the findings of this study to inform healthcare decisions, such as emphasizing effective screening programs and optimizing the use of healthcare resources to improve patient outcomes.

#### **Dataset Overview**

The dataset we decide to conduct our analysis of Mortality status (Alive/Dead) was sourced from Kaggle, which the dataset name is "Colorectal Cancer Global Dataset & Predictions". For the objective of this project, we only considered the data from Canada, which includes patient demographics, lifestyle risks, medical history, cancer stage, treatment types, survival chances, and healthcare costs. Key variables of we are going to investigate as follows:

## Response Variable

## · Mortality Status

Status of patients' mortality, coded as Yes or No.

## **Explanatory Variables**

## Alcohol Consumption

Status of patient's alcohol consumption, coded as Yes or No.

#### Age

Patient's age in years.

# Cancer Stage

Diagnosis stage of cancer, coded as Localized, Regional, or Metastatic.

#### Diabetes

Status of patient's diabetes, coded as Yes or No.

#### Diet Risk

Level of dietary risk, coded as Low, Moderate, or High.

#### · Early Detection

Detection of colorectal cancer at an early stage, coded as Yes or No.

## Family History

Family history of colorectal cancer, coded as Yes or No.

#### Genetic Mutation

Presence of genetic mutations for colorectal cancer, coded as Yes or No.

#### Gender

Gender of the patient, coded as Male or Female.

## • Healthcare Cost

Estimated healthcare expenditure per patient (in 1,000s of \$).

## • Inflammatory Bowel Disease

Presence of inflammatory bowel disease, coded as Yes or No.

#### • Insurance Status

Health insurance coverage, coded as Insured or Uninsured.

## Obesity BMI

BMI classification, coded as Normal, Overweight, or Obese.

## • Physical Activity

Level of physical activity, coded as Low, Moderate, or High.

## • Screening History

Cancer screening history, coded as Regular, Irregular, or Never.

## • Smoking History

Patient's smoking history, coded as Yes or No.

## • Treatment Type

Type of treatment received, coded as Surgery, Chemotherapy, Radiotherapy, or Combination.

#### • Tumor Size

Colorectal tumor size in millimeters (mm).

#### • Urban or Rural

Patient's area of residence, coded as Urban or Rural.

#### Motivation

Colorectal cancer is one of the most common cancers in Canada, and it is predicted that rectal cancer will be the fourth most common cancer in Canada by 2024, making it critical to understand the factors that influence mortality (Du Cancer, 2024). Analyzing mortality in relation to healthcare costs and early detection is crucial because it addresses issues at the intersection of patient care and healthcare policy. It is widely recognized that the earlier a cancer is detected, the higher the chance of survival, so examining the impact of early detection of rectal cancer on mortality with actual patient data can help quantify the

benefits of screening and early diagnosis efforts in Canada. Similarly, health care expenditures per patient can broadly reflect the intensity or quality of treatment received. Examining the relationship between healthcare expenditure and survival can help determine whether resources could be used more efficiently. By focusing on Canadian patients, we eliminate cross-national differences in healthcare systems, thereby providing a clearer understanding of the role of these factors within the context of a single-country healthcare system.

## **Analysis**

# **Exploratory Data Analysis (EDA)**

## **Balance of Response Variable**




Figure 1: Class Distribution of the Mortality Variable Before and After Balancing




Figure 2: Distribution of continuous variables by mortality status

## **Categorical Variables**




Figure 3: Proportion Bar plots for Categorical variables by mortality status

# Interpretation of Findings

Figure 1 illustrates the distribution before and after balancing the mortality status. Many more patients were alive than dead before balancing the data, which could bias any predictive model. To address this issue, we created a balanced subset by randomly under-sampling Canadian patients with different mortality statuses, producing the same number of "Yes" and "No" patients. This step is critical to ensure that unbalanced mortality outcomes do not compromise subsequent modeling.

Next, we examined continuous variables (age, tumor size, and healthcare costs) that may be associated with mortality status. Figure 2 shows the distribution of these variables between living and dead patients. We found that patients who died tended to be older, had larger tumor sizes, and that medical costs were typically higher for deceased patients compared to the living. The distribution of cost variables (in thousands of dollars) shows a heavier upper tail for the deceased group, suggesting that higher medical expenditures are associated with cases that ultimately result in death. These patterns suggest

that advanced age, more significant tumor burden, and higher treatment costs are associated with worse outcomes.

For the categorical variables, we plotted the proportions of patients' mortality status in each category (Figure 3) and observed some strong correlations. The cancer stage at diagnosis was a key factor, with patients with localized disease having a much higher mortality rate than patients with metastatic disease, and even patients with regional disease having a worse mortality rate than metastatic disease. Similarly, variables related to early intervention showed lower mortality in patients with a history of screening and in patients whose cancer was detected at an early stage compared with those who were not screened beforehand or who were not detected early. We also noted the influence of lifestyle and health risk factors, with categories such as smoking history, heavy alcohol consumption, obesity, poor diet and comorbidities tending to have higher mortality rates in the "yes" group than in the "no" group. In contrast, some factors showed little difference in mortality across categories, such as patient gender and family history of colorectal cancer, which did not show a significant difference in mortality status. Overall, advanced cancer and lack of early detection were associated with significantly higher mortality, while healthy behaviors and early cancer screening/detection had higher survival rates. These observed patterns helped us screen which variables may be significant predictors of mortality status, informing our modeling strategy.

# Model Choice and Reasoning

## Logistic Regression

Given the binary nature of the outcome (mortality: dead or alive), we chose a logistic regression model to quantify the association between the covariates and mortality. The model was applied to dichotomous responses and provided interpretable coefficients based on the odds ratio of mortality. EDA revealed a strong effect of cancer stage and early detection on the results, suggesting that a multivariate logistic approach would help analyze the model while controlling for other factors. Before fitting the model, we ensured that the key assumptions:

## **Assumption Check**

## **Binary Response**

The response variable is binary by definition, satisfying the requirement for logistic regression. We coded "Mortality" as a factor with two levels (Alive/Dead) and used the balanced dataset for modeling.

#### **Independence**

Each record corresponds to a unique patient, and we confirmed there were no duplicate entries. Thus, we can assume independence of observations.

#### Variance Structure




Figure 4: Variance peaks at predicted probability = 0.5.

In logistic regression, the variance of the residuals is not constant but is a function of the predicted probability  $\hat{\pi}$ . We plotted the predicted probabilities from the full model against the binomial variance (Figure 4). The plot showed that the variance is low at extreme predicted probabilities and peaks when  $\hat{\pi}$  is almost equal to 0.5, forming the characteristic parabolic shape. The highest uncertainty occurs at about 50% of predicted risk of death, which is consistent with theory and suggests that the model's probability estimates are correct.

## Linearity




Figure 5: Linearity check - logit of mortality plotted against continuous variables

#### **Feature Selection**




Figure 6: AIC vs Number of Covariates - demonstrating backward feature selection.

Model	Residual Deviance	AIC
Full Model	9710.7 (df = 6997)	9764.7
Backward-Selected Model	9725.6 (df = 7019)	9735.6

Table 1: Residual Deviance and AIC between the backward-selected and full models

. . .

# Statistical Analysis

<b>Test Statistic</b>	Degrees of Freedom	p-value
$\chi^2 = 0.549$	1	0.4586

Table 2: Wilks' likelihood ratio test comparison for Additive and Interaction

The result suggests the interaction term does not significantly improve model fit.

. . .

. . .

# **Results Interpretation**

inference results

Predictor	Estimate	Std. Error	z value	$\Pr(> z )$	Significance
(Intercept)	0.2256713	0.0804475	2.805	0.00503	**
Cancer_StageMetastatic	-0.0707315	0.0648033	-1.091	0.27506	
Cancer_StageRegional	-0.1151017	0.0537461	-2.142	0.03223	*
Family_HistoryYes	-0.0817314	0.0520083	-1.572	0.11607	
Healthcare_Costs	-0.0018622	0.0008735	-2.132	0.03301	*
Early_DetectionYes	-0.0081611	0.0487565	-0.167	0.86707	

Table 3: Regression output with significance levels: \* p < 0.05, \*\* p < 0.01

#### Conclusion

## **Main Findings**

This analysis identified colorectal cancer stage at diagnosis and patient health care costs as significant predictors of mortality from colorectal cancer. Specifically, mortality was much higher for advanced cancers (especially metastatic disease) compared to localized cancers, consistent with evidence that stage at diagnosis is the most important prognostic factor for colorectal cancer (Du Cancer, 2024). Higher healthcare expenditure was also significantly associated with mortality risk, which may reflect the intensive treatment needs and complications of advanced disease (Balkhi et al., 2023). In contrast, early detection status was not an independent predictor of mortality after controlling for cancer stage and other factors. This finding suggests that the benefits of early detection are mediated primarily through its impact on the diagnostic stage rather than providing an additional survival advantage (McPhail et al., 2015). These results emphasize the importance of early diagnosis of colorectal cancer in improving survival. Thus, the findings support the management of colorectal cancer patients through effective screening programs and allocating adequate healthcare resources to improve patient outcomes, emphasizing the importance of early detection.

#### Limitations

- This observational study limits the ability to establish causal relationships between predictors and mortality outcomes.
- Unmeasured confounders may also have affected the observed associations.
- The analysis lacks variables that represent systemic and contextual factors that may influence outcomes, such as regional differences in health care services or socioeconomic status.
- The variable "early detection" is defined very broadly (yes/no indicator of early detection), making its meaning somewhat ambiguous.

#### Potential Further research

Future studies could use more in-depth analyses to validate and extend these findings and examine the impact of interventions. For example, survival analyses (e.g., using Cox proportional risk models) could incorporate time-to-event data to determine in greater detail when, not just if, death occurs (Collett, 2015).

## **Appendix**

- Full regression output
- Extra plots or tables not essential to the main body
- Model selection steps

#### Reference

Balkhi, B., Alghamdi, A., Alqahtani, S., Najjar, M. A., Harbi, A. A., & Traiki, T. B. (2023). Colorectal cancer-related resource utilization and healthcare costs in Saudi Arabia. *Saudi Pharmaceutical Journal*, *31*(11), 101822. https://doi.org/10.1016/j.jsps.2023.101822

Collett, D. (2015). Modelling Survival Data in Medical Research. In *Chapman and Hall/CRC eBooks*. https://doi.org/10.1201/b18041

Du Cancer, C. C. S. /. S. C. (2024, May 1). *Colorectal cancer statistics*. Canadian Cancer Society. https://cancer.ca/en/cancer-information/cancer-types/colorectal/statistics

McPhail, S., Johnson, S., Greenberg, D., Peake, M., & Rous, B. (2015). Stage at diagnosis and early mortality from cancer in England. *British Journal of Cancer*, 112(S1), S108–S115. https://doi.org/10.1038/bjc.2015.49